Malin Corporation plc

Irish Stock Exchange MLC.IR

Malin Corporation plc EBITDA Margin for the year ending December 31, 2023

Malin Corporation plc EBITDA Margin is NA for the year ending December 31, 2023. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Malin Corporation plc EBITDA Margin for the year ending December 31, 2020 was 4.88%, a 131.53% change year over year.
Malin Corporation plc EBITDA Margin for the year ending December 31, 2019 was -15.47%, a 76.48% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Irish Stock Exchange: MLC.IR

Malin Corporation plc

CEO	Mr. William F. Daniel
IPO Date	March 25, 2014
Location	Ireland
Headquarters	The Lennox Building
Employees	3
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years